IMMX
Immix Biopharma, Inc.BS score 60.4MEDIUMPHASE2 · mkt cap $516.9M · rev ttm $0
drug hypothesis
IMX-110 modulates NOT STATED - No biological target disclosed in provided filing or trial data to treat Advanced Solid Tumors (Pancreatic Cancer, Breast Cancer, Ovarian Cancer).
moa:NOT STATED - No mechanism of action disclosed in provided materials
score breakdown
trial design70
base rate disconnect31
language red flags100
composite60.4
valuation analysis
market cap$516.9M
revenue ttm$0
phasePHASE2
historical base rate10%
disconnect ratio1.0x
lead trialNCT03382340
meta
cik0001873835
first discovered2026-04-09
last updated2026-04-10
statusACTIVE
llm model—
extracted at2026-04-10
trial design
Phase 1, non-randomized, single-arm study in patients with advanced solid tumors. Enrollment of 70 patients across multiple tumor types (pancreatic, breast, ovarian). Primary objective is safety/tolerability. Secondary endpoints include PK, response rate, PFS, OS, and duration of response.
primary endpoint:Number of participants with treatment-related adverse events assessed by CTCAE v4.03 (28 days)
claimed differentiation
NOT STATED - No differentiation claims provided in business section
language red flags
- Trial status listed as UNKNOWN - unclear if trial completed, ongoing, or terminated
- Phase 1 only with safety as primary endpoint - no efficacy signal demonstrated
- No randomized controlled design - single-arm study
- Very limited business section provided (only '7    ' visible) - insufficient information to assess company claims or strategy
- No target, mechanism, or preclinical evidence disclosed in provided materials
company-stated risks
- NOT STATED - No risk factors disclosed in provided business section